Clinical Trials Logo
  1. Home
  2. Cervical Cancer
  3. NCT06118463
  4. Details
NCT06118463 Clinical Trial

Study on AUNIP as a Novel Tumor Marker for Cervical Cancer

Cervical Cancer Clinical Trial

Official title:
Study on AUNIP as a Novel Tumor Marker for Cervical Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT06118463
Other study ID # yl20231001
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date January 1, 2024
Est. completion date January 1, 2029

Study information
Verified date November 2023
Source Qianfoshan Hospital
Contact Lin Yuan, Ph.D.
Phone 0531-89269678
Email yuanl@sdfmu.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To detect the expression of AUNIP in cervical cancer serum, and to clarify its diagnostic and prognostic value.

Description:

Blood of all study participants of cervical cancer patients are collected to detect the expression of AUNIP, analyze the statistical correlation between the expression of cervical cancer AUNIP and clinicopathological parameters of patients, and preliminarily understand the expression of AUNIP in cervical cancer tumor tissues and its clinical diagnostic and progniostic value.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 300
Est. completion date January 1, 2029
Est. primary completion date October 1, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria: Study group inclusion criteria: - Women aged 20-60 - There is a definite pathological diagnosis of cervical cancer Healthy control group: - Women aged 20-60 - No tumors in the uterus or other parts of the body - No inflammatory disease - Blood routine and blood biochemical tests are normal Exclusion Criteria: Exclusion criteria of the study group: - There are other lesions in the uterus and uterine adnexa Exclusion criteria of healthy control group: - Pregnant, lactating or menarche women - Women who are undergoing human papillomavirus (HPV) vaccination

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Detection of serum AUNIP expression
The experiment is carried out according to the ELISA kit instructions, and the absorbance optic density (OD) value of the enzyme labeler at 450 nm is read. The protein concentration of AUNIP in the serum sample is calculated according to the standard curve.

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Lin Yuan

References & Publications (2)

Ma C, Kang W, Yu L, Yang Z, Ding T. AUNIP Expression Is Correlated With Immune Infiltration and Is a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Lung Adenocarcinoma. Front Oncol. 2020 Dec 9;10:590006. doi: 10.3389/fonc.2020.590006. eCollection 2020. — View Citation

Yang Z, Liang X, Fu Y, Liu Y, Zheng L, Liu F, Li T, Yin X, Qiao X, Xu X. Identification of AUNIP as a candidate diagnostic and prognostic biomarker for oral squamous cell carcinoma. EBioMedicine. 2019 Sep;47:44-57. doi: 10.1016/j.ebiom.2019.08.013. Epub 2019 Aug 10. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary AUNIP expression in serum Serum AUNIP expression is detected by ELISA kit. The results will be recorded seperately. through study completion, an average of 3 year
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A